MENU
NVCT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

NVCT stock forecast, quote, news & analysis

Nuvectis Pharma Inc is a biopharmaceutical company... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 12, 2026

Why Nuvectis Pharma (NVCT) Stock Is Up +15.7% in the Last 30 Days

Key Takeaways

  • NVCT shares climbed roughly +15.7% over the trailing 30 days, rising from an $18.15 close on October 13, 2026, to a $21.00 close on November 11, 2026.
  • The rebound was fueled by strong third-quarter financial results and fresh clinical momentum across the company's late-stage pipeline.
  • Nuvectis reported approximately $140.7 million in cash and equivalents as of September 30, 2026, with an expected runway into the second half of 2029.
  • Lead asset NXP100 (ciprocopan) is already approved in China for paroxysmal nocturnal hemoglobinuria (PNH) and is advancing along a U.S. regulatory path, with an FDA update anticipated before year-end.
  • NXP200 secured breakthrough therapy designation in China and presented updated Phase 1b data at ESMO, including complete responses in recurrent gliomas.
  • Despite the 30-day surge, the stock is up only about 7% over the trailing three months, reflecting a volatile path that included a steep pullback before the recent recovery.
  • For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated analysis pages.
  • Explore Trending AI Robots to see how AI-driven trading strategies are being applied across the market.

Nuvectis Pharma (NVCT) Company Overview and Market Position

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of complement-related conditions and oncology. Its pipeline is anchored by NXP100 (ciprocopan), a once-daily oral complement Factor B inhibitor, and NXP200, an oral, brain-penetrant "paradox-breaker" BRAF inhibitor for BRAF-mutated solid tumors. The company also continues development of NXP900, an SRC/YES1 kinase inhibitor.

In late June 2026, Nuvectis licensed ex-China rights to NXP100 and NXP200 from Haisco Pharmaceutical Group, a transaction that transformed the company into a late-stage developer. Investors follow NVCT closely because of its potential best-in-class assets, an expanding late-stage pipeline, and near-term regulatory catalysts in large markets such as PNH and IgA nephropathy.

Nuvectis Pharma (NVCT) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, NVCT advanced approximately +15.7%, from an $18.15 close on October 13, 2026, to $21.00 on November 11, 2026. The move was not a straight line: the shares dipped below $18 intraday in late October and again in early November before rallying sharply following the company's third-quarter report.

The quarterly picture is more muted. Over the trailing three months, the stock is up roughly 7%, moving from around $19.54 in mid-August to $21.00. That modest net gain masks considerable volatility, as the shares climbed to an intraday high near $25.93 in late August, sold off to a mid-October low near $17.68, and then recovered through early November.

What Drove NVCT Stock Price in the Last 30 Days

The recent rally was driven primarily by two catalysts. First, Nuvectis reported third-quarter 2026 results on November 4, highlighting a cash position of about $140.7 million and a projected runway into the second half of 2029. Management framed the quarter as transformational, citing the late-June Haisco licensing deal and the July 2026 marketing approval of NXP100 in China for treatment-naive PNH patients, where the drug demonstrated superiority over Soliris in a Phase 3 study.

Second, in October NXP200 was featured in an oral presentation at ESMO. Updated Phase 1b data showed deep and durable single-agent activity, including complete responses in patients with recurrent or progressive gliomas, as well as responses in patients previously treated with a BRAF inhibitor. Combined with the September breakthrough therapy designation in China, the data reinforced the view that NXP200 could emerge as a differentiated, potentially best-in-class asset.

Investor sentiment also improved around NXP100's U.S. path. Management described constructive dialogue with the FDA and indicated an update on the regulatory path is expected before year-end.

What Drove NVCT Stock Performance Over the Last Quarter

The trailing three months were defined by a company-wide transformation. Nuvectis closed its ex-China licensing agreement for NXP100 and NXP200 in late June, then strengthened its balance sheet with a $115 million follow-on offering and additional ATM proceeds in July, ending the third quarter with roughly $140.7 million in cash.

These milestones drove the stock's late-August surge above $25, as investors repriced the company from an early-stage oncology developer into a late-stage pipeline with near-term catalysts. A subsequent pullback through September and mid-October reflected profit-taking and the inherent binary risk of biotech development, before the ESMO data and third-quarter report re-established positive momentum. The quarter also brought continued progress on NXP900, whose Phase 1b program includes osimertinib and lorlatinib combination studies.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-powered trading bots. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most relevant strategies are featured in this section. The bots vary in strategy, timeframe, and performance metrics, giving traders a range of approaches to explore. The page serves as a practical starting point for investors interested in how automated, data-driven strategies can complement their own research and decision-making.

NVCT Stock Forecast Drivers: What Investors Should Watch Next

Several near-term catalysts could shape NVCT's trajectory. Investors will be watching for the company's year-end update on the FDA regulatory path for NXP100 in PNH, as well as the expected first-quarter 2027 decision on the second China marketing application for previously treated PNH patients. Additional read-throughs from ongoing Phase 2 and Phase 3 studies in IgA nephropathy and related indications could also influence sentiment.

For NXP200, a U.S. IND filing is targeted for year-end 2026, with a Phase 1b trial expected to begin in early 2027. Competition remains a key risk: Novartis' (NVS) Fabhalta is already approved in multiple indications, and AstraZeneca's (AZN) injectable C5 inhibitors continue to dominate established markets. Execution on regulatory filings, clinical timelines, and manufacturing transfer remain important variables for investors to monitor.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for NVCT with price predictions
Nov 20, 2026

NVCT's Indicator enters downward trend

The Aroon Indicator for NVCT entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator formed such a pattern. In 150 of the 165 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where NVCT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCT as a result. In 92 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

NVCT moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for NVCT just turned positive on November 06, 2026. Looking at past instances where NVCT's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.

Following a +6.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCT advanced for three days, in 250 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NVCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NVCT's P/B Ratio (75.158) is slightly higher than the industry average of (3.596). P/E Ratio (-15.841) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Why Nuvectis Pharma (NVCT) Stock Is Up +15.7% in the Last 30 Days